Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Revenue of Amicus Therapeutics, Inc. (FOLD)
Revenue in 2023 (TTM): $399.36 M
According to Amicus Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $399.36 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Amicus Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $399.36 M | $362.03 M | $-92,079,000 | $-150,101,000 | $-151,584,000 |
| 2022 | $329.23 M | $290.63 M | $-199,578,000 | $-242,039,000 | $-236,568,000 |
| 2021 | $305.51 M | $271.05 M | $-202,874,000 | $-241,554,000 | $-250,460,000 |
| 2020 | $260.89 M | $229.84 M | $-242,983,000 | $-274,254,000 | $-276,852,000 |
| 2019 | $182.24 M | $160.27 M | $-332,263,000 | $-355,910,000 | $-356,388,000 |
| 2018 | $91.25 M | $76.84 M | $-322,471,000 | $-349,089,000 | $-348,995,000 |
| 2017 | $36.93 M | $30.69 M | $-428,288,000 | $-449,121,000 | $-284,002,000 |
| 2016 | $4.96 M | $4.13 M | $-195,141,000 | $-203,781,000 | $-200,042,000 |
| 2015 | $ | $-1,833,000 | $-128,707,000 | $-132,118,000 | $-132,118,000 |
| 2014 | $1.22 M | $1.22 M | $-67,008,000 | $-70,039,000 | $-68,926,000 |
| 2013 | $363 K | $-13,129,000 | $-61,380,000 | $-63,145,000 | $-59,633,000 |
| 2012 | $18.41 M | $-1,966,000 | $-50,236,000 | $-52,030,000 | $-48,785,000 |
| 2011 | $21.43 M | $21.43 M | $-46,538,000 | $-48,041,000 | $-44,412,000 |
| 2010 | $922 K | $922 K | $-53,757,000 | $-56,075,000 | $-54,936,000 |
| 2009 | $64.36 M | $64.36 M | $-4,157,000 | $-6,567,000 | $-6,567,000 |
| 2008 | $14.97 M | $14.97 M | $-37,644,000 | $-39,355,000 | $-39,355,000 |
| 2007 | $1.78 M | $1.78 M | $-44,568,000 | $-41,167,000 | $-41,167,000 |
| 2006 | $ | $ | $-44,703,352 | $-46,344,910 | $-46,344,910 |
| 2005 | $ | $ | $-20,199,478 | $-20,584,086 | $-19,972,289 |
| 2004 | $ | $ | $-8,807,102 | $ | $-8,807,102 |
| 2003 | $ | $ | $-6,468,000 | $-6,768,000 | $-6,768,000 |